Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
CAPSULES are set to replace oils as the preferred method of CBD consumption
On-going regulatory changes in the UK and Europe look set to drive a shift in consumer habits, says Tim Phillips, founder and Managing Director, of CBD-Intel.
If his prediction is correct this will signify a significant shift in consumer behaviour with its recent research showing that almost three-quarters of UK consumers use oils compared to just 16% using capsules.
https://businesscann.com/uk-cbd-consumption-to-switch-from-oils-to-capsules-as-new-research-estimates-market-value-at-690m/
" The company says that once the inflammation process associated with COVID-19 is under control, the effects of the post COVID syndrome, sometimes called the ‘long COVID, should also be minimised.
MGC Pharma will use this sub-trial and upcoming Phase III clinical trial to prove this very hypothesis, before the commercialisation phase begins. "
The plant used in the product to "control" the inflammation is Artemisinin. Artemisinin is a chemical derived from the sweet wormwood plant, Artemisia annua which has been studied and used in medicine for a long time...
In 1972 the Chinese scientist Tu Youyou isolated artemisinin from the plant and demonstrated its effectiveness against malaria, a discovery that won her the 2015 Nobel Prize in Medicine
It is available in tablets and capsules for easy consumption and dosage control
Results are currently showing that the extracts of Artemisia annua did not block the COVID virus from entering cells but interfered with the virus’ ability to replicate, thus killing it
SO..it appears there could be a race to use the plant extract and there will surely be competition in the market place and it will be interesting to see how many different "products" get to market
I think Roby really need to get ahead of the pack and get the production of the food supplement ramped up and distributed before others enter the market ...even as a food supplement before the status of "drug" might be reached